What's in Allodynic Therapeutics, Inc's pipeline?

Allodynic Therapeutics, Inc has 3 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Allodynic Therapeutics, Inc's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, Muhammad Rahman Efendi Nasution, Nevakar, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/allodynic-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Allodynic Therapeutics, Inc — Portfolio Competitive Intelligence Brief

Allodynic Therapeutics, Inc pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 1 shared drug class
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 shared drug class
Muhammad Rahman Efendi Nasution · 1 shared drug class
Nevakar, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Allodynic Therapeutics, Inc:

Cite this brief

Drug Landscape (2026). Allodynic Therapeutics, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/allodynic-therapeutics-inc. Accessed 2026-05-16.